AKLI Key Statistics, Chart & Performance
The current stock price of AKLI is 0.432 USD. In the past month the price increased by 2.71%. In the past year, price decreased by -63.7%.
AKLI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 29.52 | 37.56B | ||
| DOCS | DOXIMITY INC-CLASS A | 25.22 | 7.79B | ||
| WAY | WAYSTAR HOLDING CORP | 22.82 | 5.85B | ||
| HTFL | HEARTFLOW INC | N/A | 2.73B | ||
| CERT | CERTARA INC | 18.3 | 1.46B | ||
| SDGR | SCHRODINGER INC | N/A | 1.35B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.24B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 649.5 | 1.10B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.07B | ||
| PHR | PHREESIA INC | N/A | 993.31M | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 8.17 | 970.77M | ||
| HSTM | HEALTHSTREAM INC | 32.4 | 653.63M |
Related stock screener links
About AKLI
Company Profile
Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing and commercializing technologies designed to directly target the physiology of the brain. The Company’s software-based medicine is designed to directly target brain function and is delivered through engaging consumer entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain. The Company’s products include EndeavorRx, Selective Stimulus Management Engine (SSME), Body Brain Trainer (BBT) and Spatial Navigation (SNAV) Engine. EndeavorRx product is measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. SSME is specifically engineered to target and activate the systems in the brain that play a key role in attention function.
Company Info
AKILI INC
71 Commercial Street, Mailbox 312
Boston MASSACHUSETTS US
Employees: 66
Phone: 16174560597
AKILI INC / AKLI FAQ
What does AKILI INC do?
Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing and commercializing technologies designed to directly target the physiology of the brain. The Company’s software-based medicine is designed to directly target brain function and is delivered through engaging consumer entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain. The Company’s products include EndeavorRx, Selective Stimulus Management Engine (SSME), Body Brain Trainer (BBT) and Spatial Navigation (SNAV) Engine. EndeavorRx product is measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. SSME is specifically engineered to target and activate the systems in the brain that play a key role in attention function.
Can you provide the latest stock price for AKILI INC?
The current stock price of AKLI is 0.432 USD. The price decreased by -0.62% in the last trading session.
Does AKLI stock pay dividends?
AKLI does not pay a dividend.
What is the ChartMill technical and fundamental rating of AKLI stock?
AKLI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does AKILI INC belong to?
AKILI INC (AKLI) operates in the Health Care sector and the Health Care Technology industry.
What is the market capitalization of AKLI stock?
AKILI INC (AKLI) has a market capitalization of 34.01M USD. This makes AKLI a Nano Cap stock.
AKLI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AKLI. When comparing the yearly performance of all stocks, AKLI turns out to be only a medium performer in the overall market: it outperformed 53.94% of all stocks.
AKLI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AKLI. While AKLI seems to be doing ok healthwise, there are quite some concerns on its profitability.
AKLI Financial Highlights
Over the last trailing twelve months AKLI reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -242.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.07% | ||
| ROE | -96.7% | ||
| Debt/Equity | 0.08 |
AKLI Forecast & Estimates
6 analysts have analysed AKLI and the average price target is 0.66 USD. This implies a price increase of 53.47% is expected in the next year compared to the current price of 0.432.
For the next year, analysts expect an EPS growth of 19.97% and a revenue growth 94.59% for AKLI